MADRIGAL PHARMACEUTICA

Madrigal Pharmaceuticals Provides Corporate Updates and Reports First Quarter 2023 Financial Results

09 مايو 2023 07:00:02 بحسب Nasdaq GlobeNewswire

Madrigal Receives Breakthrough Therapy Designation from FDA for Resmetirom and Completes Enrollment of the Phase 3 MAESTRO-NASH Biopsy Trial

18 أبريل 2023 07:00:01 بحسب Nasdaq GlobeNewswire

Madrigal Pharmaceuticals Provides Corporate Updates and Reports 2022 Fourth Quarter and Full Year Financial Results

23 فبراير 2023 07:00:02 بحسب Nasdaq GlobeNewswire

Madrigal Pharmaceuticals Announces Participation at Three Upcoming Investor Conferences

08 فبراير 2023 07:00:01 بحسب Nasdaq GlobeNewswire

Madrigal Announces Additional Positive Results from the Pivotal Phase 3 MAESTRO-NASH Clinical Trial of Resmetirom for the Treatment of NASH with Liver Fibrosis

06 يناير 2023 07:00:00 بحسب Nasdaq GlobeNewswire

Madrigal Pharmaceuticals Announces $300+ Million in Financing Events to Advance Resmetirom Program

21 ديسمبر 2022 15:15:14 بحسب Nasdaq GlobeNewswire

Madrigal Announces Positive Topline Results from the Pivotal Phase 3 MAESTRO-NASH Clinical Trial of Resmetirom for the Treatment of NASH and Liver Fibrosis

19 ديسمبر 2022 06:00:00 بحسب Nasdaq GlobeNewswire

Madrigal Pharmaceuticals To Announce Topline Results from the Phase 3 MAESTRO-NASH Study of Resmetirom on Monday, December 19th

18 ديسمبر 2022 15:00:00 بحسب Nasdaq GlobeNewswire

Madrigal Pharmaceuticals Provides an Overview of Upcoming Resmetirom Data Presentations and Reports 2022 Third Quarter Financial Results

03 نوفمبر 2022 07:00:03 بحسب Nasdaq GlobeNewswire

Madrigal Pharmaceuticals to Participate in the H.C. Wainwright 24th Annual Global Investment Conference

07 سبتمبر 2022 07:00:04 بحسب Nasdaq GlobeNewswire

Madrigal Pharmaceuticals Initiates the MAESTRO-NASH Outcomes Study Evaluating Resmetirom for the Treatment of Patients with Compensated NASH Cirrhosis

31 أغسطس 2022 07:00:02 بحسب Nasdaq GlobeNewswire

Madrigal Pharmaceuticals Provides Clinical and Business Updates and Reports 2022 Second Quarter Financial Results

04 أغسطس 2022 07:00:08 بحسب Nasdaq GlobeNewswire

Madrigal Pharmaceuticals Presents Late-Breaking Phase 3 NASH Data and Multiple Oral Abstracts at EASL’s International Liver Congress™

25 يونيو 2022 08:00:00 بحسب Nasdaq GlobeNewswire

Madrigal Pharmaceuticals Supports International NASH Day on June 9

06 يونيو 2022 07:00:01 بحسب Nasdaq GlobeNewswire

Madrigal Pharmaceuticals Announces Participation at Three Upcoming Investor Conferences

02 يونيو 2022 07:00:03 بحسب Nasdaq GlobeNewswire

Madrigal Pharmaceuticals Announces Participation at Two Upcoming Investor Conferences

17 مايو 2022 07:00:01 بحسب Nasdaq GlobeNewswire

Madrigal Pharmaceuticals Provides Clinical and Business Updates and Reports 2022 First Quarter Financial Results

09 مايو 2022 05:30:00 بحسب Nasdaq GlobeNewswire

Madrigal Pharmaceuticals to Announce First Quarter 2022 Financial Results and Provide Clinical and Business Updates on May 9

28 أبريل 2022 07:00:02 بحسب Nasdaq GlobeNewswire

Madrigal Pharmaceuticals to Present at the Oppenheimer Healthcare Conference

09 مارس 2022 15:30:00 بحسب Nasdaq GlobeNewswire

Madrigal Pharmaceuticals Provides Business and Clinical Updates and Reports 2021 Fourth Quarter and Full Year Financial Results

24 فبراير 2022 07:00:02 بحسب Nasdaq GlobeNewswire